Global Dry Eye Disease Market: Snapshot

Dry eye disease is a common phenomenon which is likely to be experienced by an individual in his/her lifetime. Dry eye disease is a multifactorial disease which is characterized by insufficiency of tears in eye. Insufficient lubrication in eye lead to burning, sensing, redness and pain in eye. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye diseases. Aqueous deficiency dry eye disease is mostly caused by Meibomian Gland Dysfunction (MGD), where in tear producing glands are insufficient to produce the tears. Dry eye disease is treated by various methods such as medications, medical device therapies and surgical interventions.

According to various studies conducted across the globe, the prevalence of dry eye disease is estimated to be in the range of 8% to 34%. There are various associated risk factors for dry eye disease such as ageing, diabetes, refractive surgeries such as LASIK, consumption of certain medications and environmental factors such as pollution. Rise in geriatric population across the globe is estimated to surge number of patients with dry eye disease. Key players are investing on development of new treatments for dry eye disease which is projected to drive expansion of the global market. However, many of the patients and physicians rely on over the counter available artificial tears for treatment of dry eye disease in initial stage. There are few prescription medications indicated for dry eye disease treatment which are comparatively expensive. Moreover these medications work on signs and symptoms of dry eye and doesn’t treat root cause of dry eye disease.    

Transparency Market Research estimates that the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Escalating at this pace, the market, which had a valuation of US$ 5,045.2 Mn in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.

gobal dry eye disease market

Demand for Anti-inflammatory Drugs to Remain High Through Forecast Period

The dry eye disease market has been segmented on the basis of product, distribution channel and geography. On the basis of product, anti-inflammatory drugs segment is projected to lead the market in terms of revenue and continues to dominate the market during the forecast period followed by artificial tears segment. Introduction of new anti-inflammatory drug such as Lifitegrast (Xiidra) and advancements in the existing cyclosporine eye drops is estimated to propel expansion of the segment. On the basis of distribution channel, the market is segmented into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Rising Approval of Novel Drugs Pushes North America to Market’s fore

Geographically, dry eye disease market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global dry eye disease market in terms of revenue in 2016 and is projected to retain its dominant position during the forecast period from 2017 to 2025. High adoption of prescription dry eye disease drugs in the U.S. and increasing number of approvals for new drugs and devices from the U.S. FDA are some of the major factors responsible for high share held by North America in 2016. Asia Pacific is anticipated to gain market share during the forecast period owing to large patient pool, increasing per capita health care expenditure and increasing investment of key players in this market.

Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and  FCI S.A.S.

Global Dry Eye Disease Market: Overview

Dry eye is an ocular disease caused due to insufficiency or lack of tears in eye. Tears made up of three layers viz. lipids, mucin and aqueous keep eye moist and lubricated. Lack of tears lead to redness, burning, sensing and pain in eye. Dry eye disease also known as Keratoconjuctivitis Sicca is a common phenomenon, which is estimated to have prevalence of 8% to 34% across the globe. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye disease. Dry eye is a multifactorial disease, most of the currently approved prescription and currently approved dry eye treatment products are targeted to relief the signs and symptoms of dry eye disease. The choice of treatment depends upon the type and severity of dry eye disease.

Global Dry Eye Disease Market: Scope of the Study

This report on the dry eye disease market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2015 and 2025 along with the compound annual growth rate (CAGR %) from 2017 to 2025 are provided for all the segments, considering 2016 as the base year.

Market related factors such as technological developments, product innovation, expansion of healthcare infrastructure facilities around the world, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the dry eye disease market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, product development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Global Dry Eye Disease Market: Key Segments

On the basis of products, the dry eye disease market is categorized into artificial tears, anti-inflammatory drugs, punctal plugs, secretagogue and others. The anti-inflammatory drugs segment is further classified into cyclosporine, corticosteroids and lifitegrast. While the others segment include oral omega supplements, oral tetracycline and eye inserts. On the basis of distribution channel, the dry eye disease market is categorized into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Global Dry Eye Disease Market: Regional Outlook

On the basis of geography, the dry eye disease market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America comprises the U.S. and Canada. Europe comprises Germany, France, U.K., Spain, Italy and Rest of Europe. Asia-Pacific comprises China, India, Japan, Australia & New Zealand and Rest of Asia Pacific. Latin America comprises Brazil, Mexico and Rest of Latin America.  Middle East & Africa comprises of GCC Countries, South Africa and Rest of Middle East & Africa.

Global Dry Eye Disease Market: Competitive Outlook

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the dry eye disease market. The report also profiles major players in the dry eye disease market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and  FCI S.A.S.

The global dry eye disease market has been segmented as follows:           

Global Dry Eye Disease Market, by Product

  • Artificial Tears
  • Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Punctal Plugs
  • Secretagogue
  • Others

Global Dry Eye Disease Market, by Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies

Global Dry Eye Disease Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of MEA